About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker PBYI · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 2, 2026A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757 · Small Cell Lung Cancer ( SCLC )
Alisertib, Alisertib
PBYI
Puma Biotechnology, Inc.
Phase 2Recruiting50Mar 31, 2028Registry ↗
Oct 1, 2026A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negat…
NCT06369285 · Hormone Receptor Positive HER-2 Negative Breast Cancer, Met…
Alisertib, Endocrine therapy
PBYI
Puma Biotechnology, Inc.
Phase 2Recruiting225Dec 30, 2027Registry ↗
Aug 17, 2026A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505 · Small Cell Lung Cancer
Alisertib
PBYI
Puma Biotechnology, Inc.
Phase 2Recruiting120Oct 30, 2027Registry ↗
Mar 12, 2024Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18…
NCT01953926 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutatio…
Neratinib, Fulvestrant
PBYI
Puma Biotechnology, Inc.
Phase 2Terminated582Jan 2, 2023Registry ↗
Feb 10, 2023A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With…
NCT04366713 · HER2 Amplified Breast Cancer
Neratinib, Capecitabine
PBYI
Puma Biotechnology, Inc.
Phase 2Completed6Dec 28, 2021Registry ↗
May 6, 2022An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-S…
NCT02400476 · Early Stage HER2+ Breast Cancer
Neratinib, Loperamide
PBYI
Puma Biotechnology, Inc.
Phase 2Completed563Apr 22, 2021Registry ↗
Jun 11, 2021A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Me…
NCT01808573 · HER2+ Metastatic Breast Cancer (MBC)
neratinib, capecitabine
PBYI
Puma Biotechnology, Inc.
Phase 3Completed621Sep 28, 2018Registry ↗
Jun 11, 2021Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Brea…
NCT00878709 · Breast Cancer
neratinib, placebo
PBYI
Puma Biotechnology, Inc.
Phase 3Completed2,840Aug 21, 2014Registry ↗
May 19, 2021HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into…
NCT03786107 · Hormone Receptor-Positive, HER2-Negative Metastatic Breast…
Almac HER-Seq Assay
PBYI
Puma Biotechnology, Inc.
—Terminated1,583Jan 21, 2021Registry ↗
Dec 19, 2018A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
NCT01128842 · Advanced Malignant Solid Tumors
Neratinib, Capecitabine
PBYI
Puma Biotechnology, Inc.
Phase 1Completed7Mar 2011Registry ↗
Nov 19, 2018Study Evaluating Safety And Tolerability, Solid Tumor
NCT00768469 · Advanced Malignant Solid Tumors
Neratinib, Paclitaxel
PBYI
Puma Biotechnology, Inc.
Phase 1Completed10Jan 2011Registry ↗
Sep 26, 2018Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast C…
NCT01111825 · Breast Cancer
Temsirolimus, Neratinib
PBYI
Puma Biotechnology, Inc.
Phase 1/2Completed99Jul 2016Registry ↗
Sep 18, 2018Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
NCT00838539 · Neoplasms, Malignant Carcinoma
Neratinib, Temsirolimus
PBYI
Puma Biotechnology, Inc.
Phase 1Completed63Jun 2011Registry ↗
Sep 17, 2018Study Evaluating HKI-272 in Tumors
NCT00146172 · Breast Neoplasms
neratinib
PBYI
Puma Biotechnology, Inc.
Phase 1Completed73Jan 2007Registry ↗
Sep 14, 2018A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Adv…
NCT00397046 · Tumors
neratinib
PBYI
Puma Biotechnology, Inc.
Phase 1Completed21Mar 2009Registry ↗
Sep 5, 2018Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
NCT00741260 · Breast Cancer
Neratinib, Capecitabine
PBYI
Puma Biotechnology, Inc.
Phase 1/2Completed105Nov 2010Registry ↗
Aug 22, 2018Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanc…
NCT00915018 · Breast Cancer
Neratinib, Trastuzumab
PBYI
Puma Biotechnology, Inc.
Phase 2Completed479Aug 2013Registry ↗
Aug 14, 2018Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
NCT00300781 · Breast Neoplasms, Neoplasms
neratinib
PBYI
Puma Biotechnology, Inc.
Phase 2Completed136Apr 2008Registry ↗
Aug 9, 2018Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Ca…
NCT00777101 · Advanced Breast Cancer, Breast Cancer
Neratinib, Lapatinib
PBYI
Puma Biotechnology, Inc.
Phase 2Completed233Mar 2011Registry ↗
Aug 9, 2018Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors…
NCT00706030 · Breast Cancer, Advanced Malignant Solid Tumors
neratinib, vinorelbine
PBYI
Puma Biotechnology, Inc.
Phase 1/2Completed92Oct 2009Registry ↗
Jul 26, 2018A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With So…
NCT00445458 · Advanced Breast Cancer, Advanced Malignant Solid Tumors
HKI-272, Paclitaxel
PBYI
Puma Biotechnology, Inc.
Phase 1/2Completed110May 2011Registry ↗
Jul 24, 2018A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects Wi…
NCT00398567 · Advanced Breast Cancer
HKI-272, trastuzumab
PBYI
Puma Biotechnology, Inc.
Phase 1/2Completed45Jul 31, 2009Registry ↗
Jul 3, 2018Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Ce…
NCT01827267 · HER2-mutant Non-Small Cell Lung Cancer
neratinib, temsirolimus
PBYI
Puma Biotechnology, Inc.
Phase 2Completed62Sep 20, 2016Registry ↗
Jun 28, 2018Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic…
NCT00958724 · Advanced Malignant Solid Tumors
Neratinib, Vinorelbine
PBYI
Puma Biotechnology, Inc.
Phase 1Completed6Apr 2010Registry ↗
Apr 13, 2018Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Ca…
NCT00266877 · Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
HKI-272
PBYI
Puma Biotechnology, Inc.
Phase 2Completed172Jan 2009Registry ↗
Sep 11, 2017Study Evaluating HKI-272 Administered to Healthy Subjects
NCT00366600 · Healthy
neratinib
PBYI
Puma Biotechnology, Inc.
Phase 1Completed56Dec 2006Registry ↗
May 11, 2016Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
NCT02334501 · Healthy
Lansoprazole, Neratinib
PBYI
Puma Biotechnology, Inc.
Phase 1Completed15Oct 2014Registry ↗

27 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 4:21 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances